Morphogen-IX Scientific Advisory Board
Roham Zamanian is an Associate Professor of Medicine and Director of the Adult Pulmonary Hypertension Program at Stanford University School of Medicine. Dr. Zamanian completed his medical school and residency at the University of California, Irvine Medical Center and moved to Stanford University for a fellowship in pulmonary and critical care medicine. Dr. Zamanian extended his training by completing the eBay Pulmonary Vascular Disease super-fellowship at the Vera Moulton Wall Center (VMWC) for Pulmonary Vascular Diseases at Stanford University. After completing training, he joined the faculty of the Division of Pulmonary & Critical Care and Vera Moulton Wall Center for Pulmonary Vascular Disease and in 2007 was selected as the Director of the Adult Pulmonary Hypertension Program - a rare-disease program which has grown to include seven attending physicians, 2 PH post-doctoral fellows, 4 advanced care practitioners, and 6 clinical and research staff. The Stanford Adult Pulmonary Hypertension Program evaluates and treats approximately 600-700 PH patients annually. Besides an active clinical career, Dr. Zamanian is extensively engaged in clinical translational research. He currently directs the Vera Moulton Wall Center clinical database and biobank and focuses his research on clinical characterization and impact of novel risk factors such as methamphetamine use, and biomarkers, such as insulin resistance, in pulmonary arterial hypertension. Beyond industry clinical trials and registries, Dr. Zamanian has re-focused the research mission of the Stanford PH program by collaborating with basic science faculty and implementing several proof-of-concept and Phase I and II clinical trials of novel therapeutics developed at Stanford University. Dr. Zamanian's research is currently funded by multiple grants from the National Institutes of Health and the VMWC.